A Plus Biotechnology Co., Ltd. (6918) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of A Plus Biotechnology Co., Ltd. stock TWD 90.56, price TWD 74.20, upside +22.0%, quality 67 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
46‑month range 36.07 TWD – 127.06 TWD · fair‑value band 63.40 TWD – 117.73 TWD · the 74.20 TWD price screens below the 90.56 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow A Plus Biotechnology Co. in your weekly email
Every Wednesday you see whether A Plus Biotechnology Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
A Plus Biotechnology Co., Ltd. engages in the manufacturing and wholesale of orthopedic and other medical devices. The company offers products for chest, shoulder, spine, elbow, wrist and hand, pelvic and hip, knee, foot and ankle, osteotomy, pediatric and ESF, biologics.
Show moreShow less
It also provides bone grafts. A Plus Biotechnology Co., Ltd. was founded in 2009 and is based in New Taipei City, Taiwan.
Stock analysis
A Plus Biotechnology Co., Ltd. (6918) currently trades at 74.20 TWD, while our model-based Fair Value estimate is 90.56 TWD, implying the stock looks roughly 18% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 110.84 TWD per share, and 17 of the 26 models we run sit above the 74.20 TWD price.
Bear case: the Asset-Based group reads lowest at 26.41 TWD, and 9 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 63.40 TWD (bear) to 117.73 TWD (bull), the price of 74.20 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
A Plus Biotechnology Co., Ltd. reported revenue of 836M TWD in FY2025 versus 542M TWD in FY2021, a compound +11.4%/yr. Reported net income was 169M TWD in FY2025, compounding +50.6%/yr from FY2021.
Key figures
Market cap 2.5B TWD (≈ $77.0M) Micro · P/E ratio 13.8 · P/S ratio 2.85 · EPS (TTM) 5.39 TWD · Dividend yield 6.7% · Net margin 20.9% · Return on equity 15.5% · Return on assets (EBIT) 10.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 72 out of 100 (medium confidence).
What moves the price
The share trades about 14% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 22%, 6918 screens cheaper than that median.
Fair Value models
Bear63.40 TWDFair Value 90.56 TWDBull117.73 TWD
Price 74.20 TWD · Upside +22.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.3344 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.92/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+8.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.7%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +38.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+32.2%
Dividend (yield on the price)6.7%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 25%
⚠ Rate on operating basis: 2025 sits 54% above its own trend.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+7.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +5.7% a year for the price.
Compare A Plus Biotechnology Co., Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score67 · Top 25%
Fair Value upside+22.0% · Top 25%
Profitability
Return on equity (12 months)15.5% · Top 25%
Return on assets10.9% · Top 25%
Net margin (12 months)20.9% · Top 25%
Operating margin (12 months)25.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)13.6% · Above median
Dividend yield (12 months)6.7% · Top 25%
Balance sheet
Debt / equity0.07× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)13.8× · Cheapest 25%
P/B2.00× · Pricier than median
P/S (12 months)2.85× · Cheaper than median
Price / free cash flow (fiscal year)17.4× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "A Plus Biotechnology Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/6918
Frequently asked questions
Is A Plus Biotechnology Co., Ltd. (6918) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 90.56 TWD versus a price of 74.20 TWD, about +22% upside (undervalued).
What is the fair value of 6918?
Our model-based fair value for A Plus Biotechnology Co., Ltd. is 90.56 TWD (as of Nov 9, 2026), built from audited fundamentals. The current price: 74.20 TWD.
What is the quality score of 6918?
A Plus Biotechnology Co., Ltd. has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for A Plus Biotechnology Co., Ltd. (6918)?
Our model-based price target is the fair value of 90.56 TWD (as of Nov 9, 2026) from 26 valuation models. Cautious scenario 63.40 TWD, optimistic scenario 117.73 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the A Plus Biotechnology Co., Ltd. stock forecast for 2026?
Our models put fair value at 90.56 TWD, about +22% upside versus a price of 74.20 TWD (undervalued). Cautious scenario 63.40 TWD, optimistic scenario 117.73 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of A Plus Biotechnology Co., Ltd. (6918)?
A Plus Biotechnology Co., Ltd. reported trailing-twelve-month revenue of about 888M TWD (latest available figure, as of Nov 9, 2026).
Does A Plus Biotechnology Co., Ltd. pay a dividend?
A Plus Biotechnology Co., Ltd. currently shows a dividend yield of 6.74% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of A Plus Biotechnology Co., Ltd. (6918) and when is the ex-dividend date?
A Plus Biotechnology Co., Ltd. pays a dividend of 5.00 TWD per share a year, a dividend yield of 6.7%. The last ex-dividend date was Mar 27, 2026. The payout ratio is 92.8% of earnings. Free cash flow covers the dividend 0.85 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into A Plus Biotechnology Co., Ltd. (6918)?
For today's price to be fair in a discounted-cash-flow model, A Plus Biotechnology Co., Ltd. would have to grow free cash flow by +7.4 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +11.5 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 6918 use?
Our models discount A Plus Biotechnology Co., Ltd. at 11.8 %: a base by market capitalisation (micro), damped by beta 0.09, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For A Plus Biotechnology Co., Ltd. that is +7.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has A Plus Biotechnology Co., Ltd. (6918) delivered so far?
Over the past 4 years revenue at A Plus Biotechnology Co., Ltd. grew +11.5 % a year. The price currently implies free-cash-flow growth of +7.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of A Plus Biotechnology Co., Ltd. (6918) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into A Plus Biotechnology Co., Ltd. (+7.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of A Plus Biotechnology Co., Ltd. (6918)?
The free-cash-flow yield on the price is 5.75 %: that much free cash flow A Plus Biotechnology Co., Ltd. produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of A Plus Biotechnology Co., Ltd. (6918)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For A Plus Biotechnology Co., Ltd. it is 90.56 TWD per share (as of Nov 9, 2026), against a price of 74.20 TWD. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is A Plus Biotechnology Co., Ltd. stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 6918 trades below its calculated fair value: price 74.20 TWD, fair value 90.56 TWD, a gap of about +22% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6918?
No. The price is what the market pays today (74.20 TWD); the fair value is what the company's own numbers justify (90.56 TWD). For A Plus Biotechnology Co., Ltd. the two are 16.36 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is A Plus Biotechnology Co., Ltd. worth?
The market values A Plus Biotechnology Co., Ltd. at about 2.5B TWD (market capitalisation, as of Nov 9, 2026). Per share that is 74.20 TWD; our models calculate a fair value of 90.56 TWD per share.
What do the bullish and bearish scenarios say about 6918?
Our models span a range for A Plus Biotechnology Co., Ltd.: cautious scenario 63.40 TWD, base 90.56 TWD, optimistic 117.73 TWD per share (as of Nov 9, 2026, price 74.20 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6918?
A Plus Biotechnology Co., Ltd. trades at a price-to-earnings ratio of 13.8 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 90.56 TWD is built from several models across several years. Other multiples: P/B 2.0, P/S 2.8, EV/EBITDA 8.7.
How solid is the balance sheet of A Plus Biotechnology Co., Ltd. (6918)?
Balance-sheet figures for A Plus Biotechnology Co., Ltd. (as of Nov 9, 2026): return on equity 15.5%, debt of 0.07 per unit of equity. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is 6918 from its 52-week high?
A Plus Biotechnology Co., Ltd. trades at 74.20 TWD, about 14% below its 52-week high of 86.21 TWD and 8% above the low of 68.80 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 90.56 TWD is for.
Which stocks are comparable to A Plus Biotechnology Co., Ltd.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is A Plus Biotechnology Co., Ltd. stock attractive at the current price?
The data as of Nov 9, 2026: price 74.20 TWD, calculated fair value 90.56 TWD (+22%), Quality Score 67/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6918 calculated?
We run A Plus Biotechnology Co., Ltd. through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 90.56 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. A Plus Biotechnology Co., Ltd. currently trades 18% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of A Plus Biotechnology Co., Ltd. (6918)?
The closing price on Nov 9, 2026 was 74.20 TWD. Our model-based fair value is 90.56 TWD, about +22% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with A Plus Biotechnology Co., Ltd. right now?
Solid quality (67/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (63.40 TWD to 117.73 TWD) leaves room in how you read the outcome.
Key figures of A Plus Biotechnology Co., Ltd.
How large is the market capitalisation of A Plus Biotechnology Co., Ltd. (6918)?
The market capitalisation of A Plus Biotechnology Co., Ltd. is 2.5B TWD (≈ $77.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of A Plus Biotechnology Co., Ltd. (6918)?
The price-to-sales ratio of A Plus Biotechnology Co., Ltd. is 2.85 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of A Plus Biotechnology Co., Ltd. (6918)?
Earnings per share at A Plus Biotechnology Co., Ltd. are 5.39 TWD (price ÷ EPS = P/E 13.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of A Plus Biotechnology Co., Ltd. (6918)?
The dividend yield of A Plus Biotechnology Co., Ltd. is 6.7% (payout 92.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of A Plus Biotechnology Co., Ltd. (6918)?
The net margin of A Plus Biotechnology Co., Ltd. is 20.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of A Plus Biotechnology Co., Ltd. (6918)?
The return on equity (ROE) of A Plus Biotechnology Co., Ltd. is 15.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of A Plus Biotechnology Co., Ltd. (6918)?
On an EBIT basis the return on assets of A Plus Biotechnology Co., Ltd. is 10.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of A Plus Biotechnology Co., Ltd. (6918)?
The operating margin of A Plus Biotechnology Co., Ltd. is 25.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at A Plus Biotechnology Co., Ltd. (6918)?
Revenue at A Plus Biotechnology Co., Ltd. is growing +13.6% versus a year earlier (3y avg +10.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at A Plus Biotechnology Co., Ltd. (6918)?
Earnings per share at A Plus Biotechnology Co., Ltd. are growing +19.7% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch A Plus Biotechnology Co., Ltd. in the live analysis
One click puts A Plus Biotechnology Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 9, 2026